<DOC>
	<DOCNO>NCT00200577</DOCNO>
	<brief_summary>The objective multicentric Phase III study confirm result phase I-II study ( Dreno B &amp; Al . Cancer Immunol Immunother 2002 ; 51 : 539-456 ) demonstrate preventive effect treatment TIL ( Tumor Infiltrating Lymphocytes ) combine IL2 ( Interleukin 2 ; low dose inject subcutaneously ) metastatic relapse stage III melanoma patient one invaded lymphnode .</brief_summary>
	<brief_title>Tumor Infiltrating Lymphocytes Adjuvant Therapy Melanoma</brief_title>
	<detailed_description>In open , multicentric ( Grenoble , Montpellier , Nantes , Angers , Caen , Le Mans , Poitiers , Rennes , Tours ) randomize study , select patient one invaded lymphnode confirm anatomopathological exam randomize one follow arm : 1-Control group : patient group receive treatment clinical follow-up treat group . 2- TIL-IL2 group : treat patient receive two injection TIL combine IL2 . Tumor Infiltrating Lymphocytes obtain small piece tumour tissue remove invaded lymphnode surgery . TIL grown large number laboratory 6 week . Patients randomize treatment arm receive two injection TIL ( first 6 second 10 week post-surgery ) . Administration TIL combine low dose IL2 ( 6 million U.I . per day ) inject subcutaneously J1 J5 J8 J12 follow day TIL infusion . The dose duration IL2 treatment use second injection TIL perform one month later . After 2 month adjuvant therapy , patient receive treatment . Only regular follow-up performed .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Melanoma stage III ( regional lymph node recurrence ) . Will select patient one invaded lymph node confirm anatomopathological exam lymph node excision . Absence visceral metastasis verify physical examination , chest radiography , liver echography brainchestliver CTScan . Age &lt; 75 year , gender ECOG 02 , Karnofsky &gt; 80 % . Negative pregnancy test perform screen visit fertile woman . The potentially fertile woman must use oral contraception intrauterine device ( IUD ) three month follow last injection study treatment . The patient must fully recover surgery . HIV 1/2 : The patient must negative antibody HIV 1 HIV 2 Ag P24 DGV HIV . HBV : The patient must negative antigen , positive antibody negative DNA PCR . HCV : The patient must negative antibody . HTLV ½ : The patient must negative antibody . Following laboratory result : Hemoglobin : ≥ 10 g/dl WBC : ≥ 4000/µl Lymphocytes : ≥ 700/µl Platelet count : ≥ 100.000/µl Serum creatinine : &lt; 2.0 mg/dl £ 177 mmol/l Serum Bilirubin : &lt; 2.0 mg/dl £ 34.2 mmol/l ASAT ALAT : &lt; 2.5 x upper limit normal . Exclusion criterion : Patient one invade lymph node confirm anatomopathological exam . Presence melanoma metastasis discover clinical radiological examination screen visit . Patients must receive Chemotherapy , immunotherapy radiotherapy within precede 4 week ( 6 week since prior nitrosurea mitomycin C therapy ) . Presence cardiac affection ( congestive cardiac insufficiency , coronaropathy , control HTA ) . Any serious active medical illness , example : Active systemic infection require antibiotic , coagulation disorder condition require concomitant medication allow study . Presence second active cancer surgically cure nonmelanoma skin cancer cervical carcinoma insitu . Any affection require systemic corticotherapy treatment Interferon A . Any active autoimmune disease include insulindependent diabetes immunodeficiency . The vitiligo exclusion criterion . Thyroid dysfunction responsive therapy . Positive Serology HIV , HVB , HVC HTLV1/2 . Woman pregnant nursing without effective contraception . Incapacity give write consent .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Adjuvant therapy</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>TIL</keyword>
	<keyword>melanoma</keyword>
</DOC>